Takeda Pharmaceutical Acquires PvP Biologics

Amneal Pharmaceuticals Acquires Kashiv BioSciences to Build Global Biosimilars Platform

April 22, 2026

Healthcare Services

Amneal Pharmaceuticals entered into a definitive agreement to acquire 100% of Kashiv BioSciences in a deal with $375 million in cash and $375 million in equity at closing, plus up to $350 million in contingent regulatory milestone payments and potential commercial royalties. The acquisition is expected to close in the second half of 2026 and will create a fully integrated global biosimilars platform combining Kashiv’s development and manufacturing capabilities with Amneal’s commercial scale.

Ajinomoto Co., Inc. Acquires Forge Biologics

November 13, 2023

Biotechnology

Ajinomoto Co., Inc. will acquire Forge Biologics in an all-cash transaction valued at $620 million, expanding Ajinomoto's gene therapy and plasmid/AAV manufacturing capabilities. Forge, a Columbus, Ohio–based viral vector and plasmid CDMO with a 200,000 sq ft cGMP facility and ~300+ employees, will become a consolidated subsidiary to accelerate global gene and cell therapy manufacturing capacity.

Shionogi Inc. Acquires Qpex Biopharma, Inc.

June 26, 2023

Pharmaceuticals

Shionogi Inc., the U.S. subsidiary of Shionogi & Co., Ltd., entered into a definitive agreement to acquire San Diego-based clinical-stage antimicrobial developer Qpex Biopharma, Inc. The acquisition (upfront $100 million plus up to $40 million in milestones) brings Qpex's investigational beta-lactamase inhibitor xeruborbactam and expands Shionogi's infectious disease R&D capabilities and pipeline.

Asahi Kasei Medical to Acquire Bionova Scientific

April 14, 2022

Healthcare Services

Asahi Kasei Medical, through a U.S. subsidiary, has agreed to wholly acquire Bionova Scientific, LLC, a U.S.-based biopharmaceutical CDMO providing contract process development and GMP-compliant contract manufacturing services. The acquisition will add CDMO capabilities to Asahi Kasei Medical’s existing bioprocess business and broaden know-how-driven services for next-generation antibody drugs.

Takeda Pharmaceutical Company Limited Acquires Maverick Therapeutics, Inc.

March 9, 2021

Biotechnology

Takeda exercised its option to acquire Maverick Therapeutics, obtaining Maverick's COBRA conditionally active bispecific T‑cell engager platform and lead development candidates (TAK‑186 and TAK‑280). The deal, based on a prior collaboration and equity stake, is structured for up to $525 million in upfront and potential milestone payments and will fold Maverick's R&D team into Takeda's organization.

Bayer AG Acquires Asklepios BioPharmaceutical (AskBio)

October 26, 2020

Biotechnology

Bayer AG agreed to acquire U.S.-headquartered Asklepios BioPharmaceutical (AskBio), adding AskBio's AAV-based gene therapy platform, IP and CDMO manufacturing capabilities to Bayer’s emerging cell and gene therapy unit. Bayer will pay $2.0 billion upfront plus up to $2.0 billion in potential milestone payments; existing minority shareholders TPG Capital and Vida Ventures supported the transaction.